4th Quarter - Report

ILLUMINA, INC. for ILLUMINA, INC.

Period 4th Quarter 2024 Filed Jan 21, 2025 Signed by Jason D. Kaune, Attorney & Agent for Filer

Official filing
Firm
ILLUMINA, INC.
Client
ILLUMINA, INC.
Income
—
Expenses
$400,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Budget/Appropriations BUD

H.R. 9747: Continuing Appropriations and Extensions Act, 2025; provisions related to government funding

LobbyistCovered position, as disclosed
NICOLAS MAGALLANES —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 9747 (118th)

Health Issues HCR

H.R. 2369: VALID Act of 2023; provisions related to the the Food and Drug Administration's Laboratory Developed Tests (LDT) Rule and regulation of diagnostics and lab developed tests H.R. 2407: Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act; provisions related to coverage of Multi-Cancer Early Detection (MCED) tests General discussions related to the Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization General discussions related to Cures 2.0

LobbyistCovered position, as disclosed
NICOLAS MAGALLANES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2369 (118th), H.R. 2407 (118th)

Defense DEF

H.R. 8333: BIOSECURE Act; provisions related to genomics issues pertaining to national security

LobbyistCovered position, as disclosed
NICOLAS MAGALLANES —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 8333 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.